Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
36 hedge funds and large institutions have $7.4M invested in Lumos Pharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
0% more funds holding
Funds holding: 36 → 36 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
19% less capital invested
Capital invested by funds: $9.16M → $7.4M (-$1.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Greenwich Wealth Management
Greenwich,
Connecticut
|
+$105K |
| 2 |
Millennium Management
New York
|
+$50.1K |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$35.2K |
| 4 |
PAG
Paladin Advisory Group
Clive,
Iowa
|
+$15.3K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$361K |
| 2 |
Goldman Sachs
New York
|
-$220K |
| 3 |
SC
Shay Capital
New York
|
-$181K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$57.2K |
| 5 |
VF
Virtu Financial
New York
|
-$38K |
LUMO Hedge Fund Activity: Q1 2023 in Review
36 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2023, worth a combined $7.4M — down 19% from $9.16M a quarter earlier.
Fund positioning in LUMO was balanced in Q1 2023: 5 funds opened new positions, 5 closed out, 8 added to existing stakes and 3 trimmed.
The largest buyer was Greenwich Wealth Management, opening a new position worth an estimated $105K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $361K sold.
- 36 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $7.4M of Lumos Pharma, Inc. Common Stock stock for Q1 2023, down 19% quarter-over-quarter.
- 5 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of 0 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2023 was Greenwich Wealth Management, an estimated $105K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q1 2023 was T. Rowe Price Associates, an estimated $361K sold.
Based on aggregated 13F filings for Q1 2023.